Skip to main content
Premium Trial:

Request an Annual Quote

Kinaxo, Takeda Ink Second Collaboration for Phosphoproteomics Research


Kinaxo Biotechnologies said this week it has entered a second collaboration with Takeda Pharmaceutical under which it will apply its quantitative phosphoproteomics platform PhosphoScout to drug development.

The companies' first collaboration, which they signed in 2008, involved use of Kinaxo's KinaTor chemical proteomics technology (GWDN 04/18/2008).

PhosphoScout is an LC-MS/MS based system using strong cationic exchange chromatography in combination with IMAC or TiO2 for phosphopeptide enrichment on the front end and the MaxQuant quantitative proteomics software developed in the lab of Max Planck Institute researcher Matthias Mann.

According to Kinaxo's website, the platform can measure the relative quantity of more than 15,000 phosphorylation sites in a single experiment. The company does its mass spec work on Thermo Fisher Scientific LTQ Orbitrap Velos machines.

In addition to the Takeda collaboration, Kinaxo has struck deals with other global pharma companies including AstraZeneca, Johnson & Johnson, Dalichi-Sankyo, Roche, and Bristol-Myers Squibb.

In February, drug developer Evotec announced it had signed a definitive agreement to purchase Kinaxo for up to €16 million ($22 million) in a cash and stock deal (GWDN 02/09/2011).

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.